PL2037962T3 - Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacji - Google Patents
Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacjiInfo
- Publication number
- PL2037962T3 PL2037962T3 PL07733508T PL07733508T PL2037962T3 PL 2037962 T3 PL2037962 T3 PL 2037962T3 PL 07733508 T PL07733508 T PL 07733508T PL 07733508 T PL07733508 T PL 07733508T PL 2037962 T3 PL2037962 T3 PL 2037962T3
- Authority
- PL
- Poland
- Prior art keywords
- cells
- introducing sirna
- photochemical internalisation
- internalisation
- photochemical
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0613753.3A GB0613753D0 (en) | 2006-07-11 | 2006-07-11 | Method |
| PCT/GB2007/002569 WO2008007073A2 (en) | 2006-07-11 | 2007-07-11 | Method for introducing sirna into cells by photochemical internalisation |
| EP07733508.1A EP2037962B1 (en) | 2006-07-11 | 2007-07-11 | Method for introducing sirna into cells by photochemical internalisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2037962T3 true PL2037962T3 (pl) | 2015-03-31 |
Family
ID=36955439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07733508T PL2037962T3 (pl) | 2006-07-11 | 2007-07-11 | Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacji |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20090297487A1 (pl) |
| EP (1) | EP2037962B1 (pl) |
| JP (1) | JP5269783B2 (pl) |
| CN (1) | CN101573140B (pl) |
| AU (1) | AU2007274056B2 (pl) |
| CA (1) | CA2657999C (pl) |
| DK (1) | DK2037962T3 (pl) |
| ES (1) | ES2525222T3 (pl) |
| GB (1) | GB0613753D0 (pl) |
| NO (1) | NO342202B1 (pl) |
| NZ (1) | NZ573775A (pl) |
| PL (1) | PL2037962T3 (pl) |
| RU (1) | RU2510826C2 (pl) |
| WO (1) | WO2008007073A2 (pl) |
| ZA (1) | ZA200810684B (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0613753D0 (en) | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
| CA2708354C (en) * | 2007-12-13 | 2018-12-11 | Polyplus-Transfection | Means for delivery of nucleic acids active for gene silencing using synthetic polymers |
| WO2009109862A2 (en) * | 2008-03-06 | 2009-09-11 | Rolf Lewensohn | Improved cancer therapeutics |
| US20100056475A1 (en) * | 2008-08-06 | 2010-03-04 | Alexander Chucholowski | Cyclodextrin conjugates |
| EP2542678B1 (en) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT |
| CN101831046B (zh) * | 2010-03-30 | 2012-10-31 | 上海交通大学 | 交联剂和聚氨酯硬质泡沫材料及其制备方法 |
| EP3369817A1 (en) | 2010-07-06 | 2018-09-05 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| EP2794881B1 (en) | 2011-12-22 | 2018-06-27 | InteRNA Technologies B.V. | Mirna for treating head and neck cancer |
| WO2013109983A1 (en) * | 2012-01-18 | 2013-07-25 | University Of Utah Research Foundation | High molecular wieght arginine-grafted bioreducible polymers |
| HUE058785T2 (hu) * | 2012-10-08 | 2022-09-28 | Biontech Delivery Tech Gmbh | Karboxilált poliamin-származékok, mint transzfekciós reagensek |
| WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| HRP20190071T1 (hr) | 2013-07-12 | 2019-02-22 | F. Hoffmann - La Roche Ag | Elucidacija optimizacije unosa kromatografijom ionske izmjene |
| CA2922320C (en) * | 2013-08-28 | 2022-11-22 | Pci Biotech As | Enhanced photochemical internalisation using a tlr ligand |
| EP3034539A1 (en) * | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
| GB201503776D0 (en) | 2015-03-05 | 2015-04-22 | Pci Biotech As | Compound and method |
| CN104878044B (zh) * | 2015-04-29 | 2018-07-17 | 常州百代生物科技有限公司 | 一种脂类化合物siRNA转染试剂 |
| WO2017191219A1 (en) * | 2016-05-05 | 2017-11-09 | Cosmophos Ltd | Nano-systems for therapy and/or diagnosis and/or therapy monitoring and/or theranostics of disease |
| CN106924746B (zh) * | 2017-03-03 | 2020-11-03 | 中山大学 | 复合基因载体及其应用 |
| CN107011511B (zh) * | 2017-06-01 | 2019-04-26 | 西南大学 | 一种原卟啉荧光碳点及制备方法和应用 |
| WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
| EP3704250A1 (en) | 2017-11-03 | 2020-09-09 | InteRNA Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| GB201801169D0 (en) * | 2018-01-24 | 2018-03-07 | Pci Biotech As | Method |
| TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒（ａａｖ）之組成物和方法 |
| US12060567B2 (en) | 2018-06-13 | 2024-08-13 | Voyager Therapeutics, Inc. | Engineered untranslated regions (UTR) for AAV production |
| MX2021000810A (es) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Sistemas y metodos para producir formulaciones de terapia genetica. |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CN113166781A (zh) | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
| EP3911410A1 (en) | 2019-01-18 | 2021-11-24 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
| US20220243225A1 (en) | 2019-04-29 | 2022-08-04 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4022070A1 (en) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
| GB202101726D0 (en) | 2021-02-08 | 2021-03-24 | Pci Biotech As | Method |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| EP4301768A2 (en) | 2021-03-03 | 2024-01-10 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CN114452406B (zh) * | 2022-03-16 | 2023-05-23 | 安徽工程大学 | 一种抑菌材料及其制备方法和应用 |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| EP4642911A2 (en) | 2022-12-29 | 2025-11-05 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| CN118207158B (zh) * | 2023-06-21 | 2024-08-27 | 天津医科大学眼科医院 | 一种细胞内来源的纳米囊泡的制备方法及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| RU2066552C1 (ru) | 1996-02-12 | 1996-09-20 | Товарищество с ограниченной ответственностью "Био Прогресс" | Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней |
| FR2763943B1 (fr) * | 1997-05-28 | 1999-07-09 | Rhone Poulenc Rorer Sa | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules |
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| KR100980153B1 (ko) | 2000-11-29 | 2010-09-03 | 피씨아이 바이오테크 에이에스 | 사이토졸 내로의 분자 전달을 위한 광화학적 내부이행 |
| CA2430334C (en) | 2000-11-29 | 2018-08-21 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cytosol |
| KR100909681B1 (ko) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| KR20050084607A (ko) * | 2002-09-28 | 2005-08-26 | 매사추세츠 인스티튜트 오브 테크놀로지 | 인플루엔자 치료제 |
| CA2506714A1 (en) * | 2002-11-26 | 2004-06-10 | University Of Massachusetts | Delivery of sirnas |
| FR2858628B1 (fr) | 2003-08-04 | 2008-01-04 | Polyplus Transfection | Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines |
| GB0415263D0 (en) * | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| GB0613753D0 (en) | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
-
2006
- 2006-07-11 GB GBGB0613753.3A patent/GB0613753D0/en not_active Ceased
-
2007
- 2007-07-11 JP JP2009518954A patent/JP5269783B2/ja not_active Expired - Fee Related
- 2007-07-11 US US12/304,266 patent/US20090297487A1/en not_active Abandoned
- 2007-07-11 EP EP07733508.1A patent/EP2037962B1/en active Active
- 2007-07-11 PL PL07733508T patent/PL2037962T3/pl unknown
- 2007-07-11 ZA ZA200810684A patent/ZA200810684B/xx unknown
- 2007-07-11 DK DK07733508.1T patent/DK2037962T3/en active
- 2007-07-11 CA CA2657999A patent/CA2657999C/en active Active
- 2007-07-11 NZ NZ573775A patent/NZ573775A/xx not_active IP Right Cessation
- 2007-07-11 RU RU2008150847/10A patent/RU2510826C2/ru active
- 2007-07-11 CN CN200780024620.7A patent/CN101573140B/zh not_active Expired - Fee Related
- 2007-07-11 ES ES07733508.1T patent/ES2525222T3/es active Active
- 2007-07-11 AU AU2007274056A patent/AU2007274056B2/en not_active Ceased
- 2007-07-11 WO PCT/GB2007/002569 patent/WO2008007073A2/en not_active Ceased
-
2008
- 2008-12-16 NO NO20085259A patent/NO342202B1/no not_active IP Right Cessation
-
2012
- 2012-01-12 US US13/349,334 patent/US9700622B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2657999C (en) | 2015-02-24 |
| JP5269783B2 (ja) | 2013-08-21 |
| NO342202B1 (no) | 2018-04-16 |
| RU2008150847A (ru) | 2010-06-27 |
| CN101573140A (zh) | 2009-11-04 |
| EP2037962A2 (en) | 2009-03-25 |
| US20120264807A1 (en) | 2012-10-18 |
| WO2008007073A3 (en) | 2008-04-10 |
| WO2008007073A2 (en) | 2008-01-17 |
| AU2007274056A1 (en) | 2008-01-17 |
| NZ573775A (en) | 2012-11-30 |
| ES2525222T3 (es) | 2014-12-19 |
| ZA200810684B (en) | 2010-08-25 |
| GB0613753D0 (en) | 2006-08-23 |
| NO20085259L (no) | 2009-02-10 |
| US20090297487A1 (en) | 2009-12-03 |
| CA2657999A1 (en) | 2008-01-17 |
| AU2007274056B2 (en) | 2013-08-01 |
| JP2010504080A (ja) | 2010-02-12 |
| RU2510826C2 (ru) | 2014-04-10 |
| CN101573140B (zh) | 2014-04-23 |
| DK2037962T3 (en) | 2014-12-15 |
| EP2037962B1 (en) | 2014-09-03 |
| US9700622B2 (en) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200810684B (en) | Method for introducing sirna into cells by photochemical internalisation | |
| EP2277993A4 (en) | PROCESS FOR PRODUCING ENDOTHELIAL CELLS (AND VARIANTS) | |
| ZA201003193B (en) | Method for producing dendritic cells | |
| ZA201001753B (en) | Method for consumer-dispenser interactions | |
| EP2198019A4 (en) | PROCESS FOR PRODUCING CELLULASE | |
| PT2096102E (pt) | Processo para a produção de metileno-difenil-diisocianatos | |
| EP2123631A4 (en) | PROCESS FOR PRODUCTION OF -ALCOXYPROPIONAMIDE | |
| IL206155A0 (en) | Method for increasing immunoreactivity | |
| PL2365938T3 (pl) | Sposób odsiarczania | |
| PL2252691T3 (pl) | Sposób otrzymywania alfa-santalenu | |
| PL2150294T3 (pl) | Sposób pozyskiwania komórek | |
| EP2328900A4 (en) | PROCESS FOR PREPARING MORPHINAN-6 alpha-OLS | |
| GB0810558D0 (en) | Method for cell manipulation | |
| PL2441462T3 (pl) | Sposób leczenia cukrzycy typu I | |
| IL210051A0 (en) | Method for producing aminobiphenylene | |
| EP2371943A4 (en) | METHOD FOR WASHING CELLS | |
| TWI350280B (en) | Method for refining glycerin | |
| GB2456999B (en) | Method for preparing 2-deoxy-L-ribose | |
| ZA200901945B (en) | Hydrogen production method | |
| GB0814443D0 (en) | Process for cultivating cells | |
| EP2216408A4 (en) | METHOD FOR IMPROVING SALINITY TOLERANCE | |
| IL207656A0 (en) | Method for producing continuous cell lines | |
| GB0719218D0 (en) | Process tank | |
| EP2097408A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF EPROSARTAN | |
| IL210353A0 (en) | Method for producing phenylalkane - 1 - ols |